Zambia breaks ground on ZAMVAX cholera vaccine manufacturing plant

The facility is a joint venture between China’s Jijia International Medical Technology Co., Ltd. and Zambia’s Industrial Development Corporation (IDC).

ZAMBIA—Zambia has launched construction of the ZAMVAX vaccine manufacturing facility to expand local cholera vaccine production and strengthen public health preparedness.

Minister Counsellor Wang Sheng attended the groundbreaking ceremony alongside Health Minister Prof. Roma Chilengi, senior government officials and representatives of Chinese and Zambian businesses.

The facility is a joint venture between China’s Jijia International Medical Technology Co., Ltd. and Zambia’s Industrial Development Corporation (IDC).

The project aims to establish local vaccine manufacturing capacity, reduce dependence on imported vaccines and improve access to essential immunisation products.

Strengthening local vaccine production

Speaking at the ceremony, Prof. Chilengi thanked the Chinese Government for its continued support for Zambia’s public health sector.

He noted that the facility would strengthen the country’s healthcare system by improving its capacity to prevent and control infectious diseases.

The minister also highlighted the project’s potential to serve neighbouring countries, positioning Zambia as a regional supplier of vaccines.

Increased local production could improve supply security, support regional disease prevention programmes and contribute to the development of the country’s pharmaceutical manufacturing industry.

China-Zambia health cooperation

Wang Sheng described the project as an outcome of the Ten Partnership Actions announced at the 2024 Forum on China-Africa Cooperation (FOCAC) Beijing Summit.

He noted that the facility would be the first in Africa dedicated to cholera vaccine manufacturing.

Once operational, the plant is expected to address gaps in Zambia’s domestic vaccine production, reduce reliance on external suppliers and strengthen the country’s ability to respond to public health emergencies.

The project will also support the training of local professionals in vaccine manufacturing and public health.

Wang reaffirmed China’s commitment to working with Zambia to ensure the project meets construction and quality standards.

The two countries also intend to use the investment to expand cooperation in healthcare and related industries.

For Zambia, the facility represents an investment in pharmaceutical manufacturing capacity at a time when African countries are seeking to strengthen local production of essential health commodities.

Expanding vaccine manufacturing could also create opportunities for technology transfer, skills development and regional supply-chain integration.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and around the world, and follow us on LinkedIn for updates.

Visited 5 times, 5 visit(s) today

Newer Post

Thumbnail for Zambia breaks ground on ZAMVAX cholera vaccine manufacturing plant

Philips launches cloud-based ultrasound fleet management platform at RSNA 2026

Older Post

Thumbnail for Zambia breaks ground on ZAMVAX cholera vaccine manufacturing plant

Magrabi Health opens ENT department in Jeddah to expand specialist care

Be the first to leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *